HDIT101

HDIT101 is an experimental antibody that reached two Phase 2 HSV studies, and neither study met its primary efficacy goal.

In MATCH-2, one intravenous infusion did not show fewer lesion days than valacyclovir taken when a recurrence began in adults with recurrent genital HSV-2; recurrence counts numerically favored HDIT101 in some analyses, but those secondary tests were exploratory and did not establish efficacy.

MATCH-1 tested topical HDIT101 for recurrent oral HSV-1 and stopped early for futility, with a primary result that did not favor HDIT101.

No active next trial or ordinary clinical availability was identified, so the current program status is unclear.

HDIT101, also written HDIT-101, is a laboratory-made antibody designed to recognize a conserved site on HSV glycoprotein B found on HSV-1 and HSV-2 virus particles and infected cells.

Its laboratory precursor neutralized extracellular HSV-1 and HSV-2 and inhibited cell-to-cell spread in cell-culture models, but those experiments did not establish benefit in people.

The clinical program tested whether an antibody directed at HSV glycoprotein B could reduce recurrent disease after either intravenous or topical administration.

MATCH-2 compared one intravenous dose with valacyclovir taken for each recurrence of genital HSV-2, while MATCH-1 compared topical HDIT101 with placebo for recurrent oral HSV-1.

A first-in-human study randomized 24 healthy volunteers across six single intravenous dose levels, with 18 receiving HDIT101 and six receiving placebo.

That four-week study assessed short-term safety and pharmacokinetics rather than efficacy in people with HSV disease.

MATCH-2 then randomized 122 adults with recurrent anogenital HSV-2 and completed without meeting its primary superiority endpoint.

MATCH-1 enrolled 761 people into a longer observation and screening pathway, but the regulatory results record shows that 158 received assigned study treatment before the trial stopped early for futility.

In the MATCH-2 full analysis set, the mean percentage of days with lesions was 15.6% with HDIT101 and 14.3% with episodic valacyclovir, with p=0.58.

The corresponding per-protocol means were 14.6% and 14.9%, so the trial did not demonstrate superiority on its primary endpoint.

Because that primary analysis was not significant, the study's prespecified testing hierarchy made all secondary statistical comparisons exploratory.

Mean recurrence counts were 3.2 with HDIT101 and 3.8 with valacyclovir in the full analysis set, with p=0.07, and 2.7 versus 3.8 in the per-protocol set, with a nominal p=0.01.

Time to first recurrence was not statistically significant, and the study showed no superiority for HSV-2 shedding or a detected difference in reported quality of life.

In MATCH-1, the mean number of recurrences was 3.1 with topical HDIT101 and 2.3 with placebo, with a prespecified rate ratio of 1.442 and a 95% confidence interval from 1.08 to 1.93, where a lower value would have favored HDIT101.

MATCH-1 therefore did not demonstrate superiority on its primary endpoint, and the disclosed secondary results also did not numerically favor HDIT101.

HDIT101 has controlled human efficacy evidence, but the Phase 2 evidence is mixed and predominantly negative for the regimens tested.

The per-protocol recurrence-rate result in MATCH-2 may be a reason to study another regimen, but it does not overturn the failed primary endpoint or confirm that HDIT101 works.

MATCH-1's result is negative evidence for the tested topical HSV-1 regimen, not proof that every dose, route, or HSV indication would fail.

Neither study showed that HDIT101 cures HSV or prevents transmission to another person.

The current program status is unclear.

The developer's undated pages still describe the Phase 2 studies as ongoing and HDIT101 as under development, but later records show that MATCH-2 completed and MATCH-1 terminated.

No checked direct source established an active next HDIT101 trial, a commercial development partner, a restart, or a permanent discontinuation decision through September 4, 2026.

The developer has continued laboratory work on a second anti-glycoprotein-B antibody, HDIT102, publishing a full characterization in 2024 and still prosecuting patents on it and on a two-antibody combination in April 2026. That work is laboratory and animal work. HDIT102 has never been given to a person in any study identified through September 9, 2026, so it is not human evidence for HDIT102 and adds no human evidence for HDIT101.

HDIT102 does not appear on the developer's website and is not mentioned in the developer's own 2025 report of the MATCH-2 trial, which instead proposes repeated doses of HDIT101 as a possible future direction. That HDIT102 exists and is still being patented does not establish that it is being developed, and its absence from the developer's public material does not establish that it has been dropped.

The checked sources also did not identify regulatory approval or ordinary clinical availability for HDIT101.

No confirmed development milestone was identified.

This record should be updated if the developer announces a new protocol or program decision, or if fuller MATCH-1 analyses become public.

A registered trial of HDIT102, in combination with HDIT101 or alone, would be the first evidence that the second antibody has entered development. None exists in the checked registries.